Abingdon Health PLC (AIM:ABDX) shares were on the front foot Wednesday morning after tits saliva-based pregnancy test was launched with online and high-street retailer and pharmacy Boots.
It was developed through partnerships with Salignostics and Crest Medical.
The product range will be sold exclusively in the UK by Boots and marks the latest product launch by the company following its tests for iron and vitamin D deficiencies.
"We are delighted to announce the launch of the Boots branded saliva pregnancy test in conjunction with our partners Salignostics and Crest Medical,” chief executive Chris Yates said in a statement.
“This launch showcases our ability to deliver innovative and disruptive private label products through our CDMO/CRO lateral flow full-service proposition with one of the most trusted UK brands - Boots."
In London, Abingdon shares were up 7.7% changing hands at 10.50p each.